ILMN Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of 16.94% compared to Illumina's net margin of 8.47%. Illumina's return on equity of -35.09% beat Quest Diagnostics's return on equity of 12.99%.

Illumina has a consensus price target of $130.64, signalling upside risk potential of 63.31%. On the other hand Quest Diagnostics has an analysts' consensus of $177.10 which suggests that it could grow by 5.84%. Given that Illumina has higher upside potential than Quest Diagnostics, analysts believe Illumina is more attractive than Quest Diagnostics.

Illumina has a beta of 1.171, which suggesting that the stock is 17.134% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.577%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.79% to investors and pays a quarterly dividend of $0.75 per share. Illumina pays -- of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Quest Diagnostics quarterly revenues of $2.6B. Illumina's net income of $187M is lower than Quest Diagnostics's net income of $222M. Notably, Illumina's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 21.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.91x versus 1.92x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Danaher has a net margin of 16.94% compared to Illumina's net margin of 16.61%. Illumina's return on equity of -35.09% beat Danaher's return on equity of 7.57%.

Illumina has a consensus price target of $130.64, signalling upside risk potential of 63.31%. On the other hand Danaher has an analysts' consensus of $265.19 which suggests that it could grow by 28.83%. Given that Illumina has higher upside potential than Danaher, analysts believe Illumina is more attractive than Danaher.

Illumina has a beta of 1.171, which suggesting that the stock is 17.134% more volatile than S&P 500. In comparison Danaher has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.66%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher offers a yield of 0.55% to investors and pays a quarterly dividend of $0.32 per share. Illumina pays -- of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Danaher quarterly revenues of $6.5B. Illumina's net income of $187M is lower than Danaher's net income of $1.1B. Notably, Illumina's price-to-earnings ratio is -- while Danaher's PE ratio is 38.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.91x versus 6.36x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 16.94% compared to Illumina's net margin of -121.19%. Illumina's return on equity of -35.09% beat Exact Sciences's return on equity of -34.11%.

Illumina has a consensus price target of $130.64, signalling upside risk potential of 63.31%. On the other hand Exact Sciences has an analysts' consensus of $68.89 which suggests that it could grow by 57.78%. Given that Illumina has higher upside potential than Exact Sciences, analysts believe Illumina is more attractive than Exact Sciences.

Illumina has a beta of 1.171, which suggesting that the stock is 17.134% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.248, suggesting its more volatile than the S&P 500 by 24.844%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Illumina quarterly revenues are $1.1B, which are larger than Exact Sciences quarterly revenues of $713.4M. Illumina's net income of $187M is higher than Exact Sciences's net income of -$864.6M. Notably, Illumina's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.91x versus 2.91x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 16.94% compared to Illumina's net margin of 4.31%. Illumina's return on equity of -35.09% beat Labcorp Holdings's return on equity of 9.29%.

Illumina has a consensus price target of $130.64, signalling upside risk potential of 63.31%. On the other hand Labcorp Holdings has an analysts' consensus of $273.60 which suggests that it could grow by 18.94%. Given that Illumina has higher upside potential than Labcorp Holdings, analysts believe Illumina is more attractive than Labcorp Holdings.

Illumina has a beta of 1.171, which suggesting that the stock is 17.134% more volatile than S&P 500. In comparison Labcorp Holdings has a beta of 1.122, suggesting its more volatile than the S&P 500 by 12.207%.

Illumina has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.25% to investors and pays a quarterly dividend of $0.72 per share. Illumina pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Illumina quarterly revenues are $1.1B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Illumina's net income of $187M is higher than Labcorp Holdings's net income of $143.4M. Notably, Illumina's price-to-earnings ratio is -- while Labcorp Holdings's PE ratio is 26.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina is 2.91x versus 1.49x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.